Akebia Therapeutics
(NASDAQ) AKBA
Akebia Therapeutics Financials at a Glance
Market Cap
$358.96M
Revenue (TTM)
$236.19M
Net Income (TTM)
$5.34M
EPS (TTM)
$-0.02
P/E Ratio
-74.44
Dividend
$0.00
Beta (Volatility)
1.50 (Average)
Dividend
$0.00
Beta (Volatility)
1.50 (Average)
Price
$1.34
Volume
75,495
Open
$1.38
Price
$1.34
Volume
75,495
Open
$1.38
Previous Close
$1.34
Daily Range
$1.32 - $1.38
52-Week Range
$1.14 - $4.08
Dividend
$0.00
Beta (Volatility)
1.50 (Average)
Price
$1.34
Volume
75,495
Open
$1.38
Previous Close
$1.34
Daily Range
$1.32 - $1.38
52-Week Range
$1.14 - $4.08
AKBA News
AKBA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Akebia Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
194
CEO
John P. Butler, MBA
Website
www.akebia.comHeadquarters
Cambridge, MA 02142, US
AKBA Financials
Key Financial Metrics (TTM)
Gross Margin
83%
Operating Margin
10%
Net Income Margin
-2%
Return on Equity
0%
Return on Capital
11%
Return on Assets
-1%
Earnings Yield
-1.34%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$358.96M
Shares Outstanding
267.88M
Volume
75.50K
Short Interest
0.00%
Avg. Volume
3.24M
Financials (TTM)
Gross Profit
$196.73M
Operating Income
$23.50M
EBITDA
$21.73M
Operating Cash Flow
$67.99M
Capital Expenditure
$291.00K
Free Cash Flow
$67.99M
Cash & ST Invst.
$184.84M
Total Debt
$216.30M
Akebia Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$57.62M
+23.9%
Gross Profit
$45.41M
+73.8%
Gross Margin
78.80%
N/A
Market Cap
$358.96M
N/A
Market Cap/Employee
$1.98M
N/A
Employees
181
N/A
Net Income
$12.24M
+46.3%
EBITDA
$6.09M
+7.5%
Quarterly Fundamentals
Net Cash
$31.45M
+77.0%
Accounts Receivable
$47.03M
+36.8%
Inventory
$0.00
-100.0%
Long Term Debt
$176.21M
-1.6%
Short Term Debt
$43.63M
+349.2%
Return on Assets
-1.42%
N/A
Return on Invested Capital
11.00%
N/A
Free Cash Flow
$30.97M
+793.1%
Operating Cash Flow
$31.13M
+797.0%